Carderock Capital Management Inc. Reduces Position in Abbott Laboratories (ABT)

The Hall Laurie J Trustee holds 68,526 shares with $3.33 billion value, up from 66,316 last quarter. Abbott Laboratories now has $97.70 billion valuation. Deutsche Bank maintained Abbott Laboratories (NYSE:ABT) on Friday, July 21 with "Buy" rating. Institutional investors own 62.20% of the company's stock. Kanaly Trust Co boosted its stake in Abbott Laboratories by 3.7% in the third quarter. About 2.15M shares traded. 102 funds opened positions while 441 raised stakes. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker's stock valued at $131,000 after buying an additional 2,094 shares during the period. JFS Wealth Advisors LLC grew its holdings in Abbott Laboratories by 349.0% in the second quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker's stock worth $264,000 after buying an additional 30 shares during the last quarter. Motco grew its holdings in Abbott Laboratories by 213.7% in the second quarter. Following the completion of the sale, the insider now directly owns 10,256 shares of the company's stock, valued at $572,900.16. The firm owned 3,142 shares of the healthcare product maker's stock at the end of the first quarter. Investors measure stock performance on the basis of a company's earnings power. Also, insider Alejandro D. Wellisch sold 2,153 shares of the stock in a transaction dated Wednesday, November 22nd.

In other news, insider Jaime Contreras sold 52,700 shares of the stock in a transaction that occurred on Friday, September 22nd. Active and passive investors always require every bit of information available regarding his chosen security and this include keeping close watch on fundamental and technical data. Barclays Capital maintained Abbott Laboratories (NYSE:ABT) on Thursday, April 20 with "Overweight" rating. The stock was sold at an average price of $56.21, for a total value of $5,430,054.63. The disclosure for this sale can be found here. The Raymond James Trust holds 175,478 shares with $8.53M value, up from 163,719 last quarter. Motco now owns 2,880 shares of the healthcare product maker's stock valued at $140,000 after purchasing an additional 1,962 shares during the period.

Several research firms have weighed in on ABT. Zacks Investment Research raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and set a $61.00 price objective on the stock in a research note on Tuesday, October 31st.

Abbott Laboratories (ABT) traded up $0.09 during mid-day trading on Monday, reaching $56.23. During the same period in the previous year, the company posted $0.59 earnings per share. research analysts predict that Abbott Laboratories will post 2.49 EPS for the current fiscal year. Eubel Brady & Suttman Asset Management reported 0.14% of its portfolio in Abbott Laboratories (NYSE:ABT). Of the 19 analysts surveyed by Reuters that track ABT 6 of them rate its stock a hold. The firm has "Buy" rating by RBC Capital Markets given on Friday, September 1. Jefferies maintained the stock with "Buy" rating in Tuesday, October 10 report. Independent Consultants has invested 0.04% in Abbott Laboratories (NYSE:ABT). Abbott Laboratories has $90 highest and $4 lowest target. The quick ratio, on the other hand, is 2.3 indicating the company's current short-term liquidity. Comparatively, Abbott Laboratories posted earnings of $0.71 per share in the same quarter past year. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.65 by $0.01.

Man Mistakes NY Woman as Deer, Shoots Her
The Chautauqua County District Attorney's Office is due to determine whether to bring a criminal case against Jadlowski. Jadlowski heard a scream and rushed to her before calling 911 and applying pressure to her wound, the office said.

Quantbot Technologies Lp increased its stake in Abbott Laboratories (ABT) by 282.99% based on its latest 2017Q2 regulatory filing with the SEC. The firm had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. Cambridge Advsr stated it has 11,010 shares. The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 2.00, which implies that analysts are generally neutral in their outlook for ABT over the next year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Security National Bank & Trust Of Sioux City Iowa Ia invested in 70 shares or 0% of the stock. It has a dividend yield of 1.89%. The ex-dividend date was Thursday, October 12th. Moreover, Marco Ltd Limited Liability Company has 1% invested in Abbott Laboratories (NYSE:ABT).

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this report on another domain, it was illegally copied and reposted in violation of USA & global copyright & trademark legislation.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products.

Related Articles